We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha said.

AbbVie has multiple growth narratives to offset HUMIRA losses and clinical trial failures (e.g., venetoclax in MDS). In Q1, SKYRIZI generated a whopping $3.425 billion in net revenues ...

AbbVie is undervalued with strong EPS growth, rising immunology revenue, and a 3.43% yield. Check out ABBV's robust pipeline and long-term value.

AbbVie is facing a major challenge to its business in the coming years with the loss of patent protection for immunology behemoth Humira (adalimumab), which saw sales plunge by a third to $11.1 ...

AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. The collaboration ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

A company expected to fare well during this time is Eli Lilly, with revenue forecast to improve by 165% in 2030. This will largely be driven by the company’s glucagon like peptide-1 receptor agonist ...

PORTLAND, OR, UNITED STATES, July 3, 2025 /EINPresswire / -- (Global value: USD 5.4 billion (2021) → USD 7.9 b ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.